The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis

Biomarkers

Volumn 13, Issue 7-8, 2008, Pages 692-712

  Stolina, Marina ^a   Bolon, Brad ^a   Dwyer, Denise ^a   Middleton, Scot ^a   Duryea, Diane ^a   Kostenuik, Paul J ^a   Feige, Ulrich ^a   Zack, Debra J ^a  

^a AMGEN INC   (United States)

Author keywords

Biomarkers; Bone resorption; Cytokines; Inflammation; Rat collagen induced arthritis

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; IMMUNOGLOBULIN; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OROSOMUCOID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOPSY; BLOOD; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; LEUKOCYTOSIS; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; RAT; SPLEEN; UPREGULATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; COLLAGEN; CYTOKINES; DISEASE PROGRESSION; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATION MEDIATORS; KINETICS; LEUKOCYTOSIS; RATS; TIME FACTORS;

RATTUS;

EID: 58049195691     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500802651911     Document Type: Article

References (61)

1. Andreakos, ET, Foxwell, BM, Brennan, FM, Maini, RN and Feldmann, M. (2002) Cytokines and anti-cytokine biologicals in autoimmunity: Present and future. Cytokine and Growth Factor Reviews, 13, pp. 299-313.
2. Arend, WP. (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthritis and Rheumatism, 45, pp. 101-106.
3. Arend, WP and Dayer, JM. (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis and Rheumatism, 33, pp. 305-315.
4. Arend, WP and Dayer, JM. (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis and Rheumatism, 38, pp. 151-160.
5. Bolon, B., Shalhoub, V., Kostenuik, PJ, Campagnuolo, G., Morony, S., Boyle, WJ, Zack, D. and Feige, U. (2002) Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis and Rheumatism, 46, pp. 3121-3135.
6. Breedveld, FC. (1999) Future trends in the treatment of rheumatoid arthritis: Cytokine targets. Rheumatology (Oxford), 38, pp. 11-13.
7. Brennan, FM, Field, M., Chu, CQ, Feldmann, M. and Maini, RN. (1991) Cytokine expression in rheumatoid arthritis. British Journal of Rheumatology, 30, pp. 76-80.
8. Bresnihan, B., Alvaro-Gracia, JM, Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., Watt, I., Williams, B., Aitchison, R., McCabe, D. and Musikic, P. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis and Rheumatism, 41, pp. 2196-2204.
9. Calabrese, LH. (2003) Molecular differences in anticytokine therapies. Clinical and Experimental Rheumatology, 21, pp. 241-248.
10. Campagnuolo, G., Bolon, B. and Feige, U. (2002) Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis and Rheumatism, 46, pp. 1926-1936.
11. Cheon, H., Yu, SJ, Yoo, DH, Chae, IJ, Song, GG and Sohn, J. (2002) Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-beta1 in synovial fibroblasts from rheumatoid arthritis and normal individuals. Clinical and Experimental Immunology, 127, pp. 547-552.
12. Cohen, SB, Dore, RK, Lane, NE, Ory, PA, Peterfy, CG, Sharp, JT, van der, HD, Zhou, L., Tsuji, W. and Newmark, R. (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis and Rheumatism, 58, pp. 1299-1309.
13. Coxon, A., Bolon, B., Estrada, J., Kaufman, S., Scully, S., Rattan, A., Duryea, D., Hu, YL, Rex, K., Pacheco, E., Van, G., Zack, D. and Feige, U. (2002) Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis and Rheumatism, 46, pp. 2604-2612.
14. Cremer, MA, Hernandez, AD, Townes, AS, Stuart, JM and Kang, AH. (1983) Collagen-induced arthritis in rats: Antigen-specific suppression of arthritis and immunity by intravenously injected native type II collagen. Journal of Immunology, 131, pp. 2995-3000.
15. Crotti, TN, Smith, MD, Weedon, H., Ahern, MJ, Findlay, DM, Kraan, M., Tak, PP and Haynes, DR. (2002) Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: Semiquantitative and quantitative analysis. Annals of the Rheumatic Diseases, 61, pp. 1047-1054.
16. Feige, U., Hu, YL, Gasser, J., Campagnuolo, G., Munyakazi, L. and Bolon, B. (2000) Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cellular and Molecular Life Sciences, 57, pp. 1457-1470.
17. Gaffen, SL. (2004) Biology of recently discovered cytokines: interleukin-17 - a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Research and Therapy, 6, pp. 240-247.
18. Geusens, PP, Landewe, R., Garnero, P., Chen, D., Dunstan, CR, Lems, WF, Stinissen, P., van der Heijde, D., van der Linden, S. and Boers, M. (2006) The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism, 54, pp. 1772-1777.
19. Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F. and Heymann, D. (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. American Journal of Pathology, 163, pp. 2021-2031.
20. Hofbauer, LC, Lacey, DL, Dunstan, CR, Spelsberg, TC, Riggs, BL and Khosla, S. (1999) Interleukin-1b and tumor necrosis factor-β, but not interleukin 6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 25, pp. 255-259.
21. Iwakura, Y. (2002) Roles of IL-1 in the development of rheumatoid arthritis: Consideration from mouse models. Cytokine and Growth Factor Reviews, 13, pp. 341-355.
22. Joosten, LA, Helsen, MM, Saxne, T., van de Loo, FA, Heinegard, D. and van den Berg, WB. (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. Journal of Immunology, 163, pp. 5049-5055.
23. Kaplan, C., Valdez, JC, Chandrasekaran, R., Eibel, H., Mikecz, K., Glant, TT and Finnegan, A. (2002) Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis Research, 4, pp. 54-58.
24. Keller, C., Webb, A. and Davis, J. (2003) Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: A brief report and literature review. Annals of the Rheumatic Diseases, 62, pp. 1128-1132.
25. Kindle, L., Rothe, L., Kriss, M., Osdoby, P. and Collin-Osdoby, P. (2006) Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts. Journal of Bone and Mineral Research, 21, pp. 193-206.
26. Koenders, MI, Lubberts, E., Oppers-Walgreen, B., van den Bersselaar, L, Helsen, MM, Di Padova, F, Boots, MH, Gram, H., Joosten, L. and van den Berg, WB. (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. American Journal of Pathology, 167, pp. 141-149.
27. Koller, MD. (2006) Targeted therapy in rheumatoid arthritis. Wiener Medizinische Wochenschrift, 156, pp. 53-60.
28. Kong, YY, Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, ER, Van, G., Nguyen, LT, Ohashi, PS, Lacey, DL, Fish, E., Boyle, WJ and Penninger, JM. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402, pp. 304-309.
29. Kourbeti, IS and Boumpas, DT. (2005) Biological therapies of autoimmune diseases. Current Drug Targets Inflammation and Allergy, 4, pp. 41-46.
30. Kuiper, S., Joosten, LA, Bendele, AM, Edwards III, CK, Arntz, OJ, Helsen, MM, van de Loo, FA and van den Berg, WB. (1998) Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine, 10, pp. 690-702.
31. Kulmatycki, KM and Jamali, F. (2005) Drug disease interactions: Role of inflammatory mediators in disease and variability in drug response. Journal of Pharmacy & Pharmaceutical Sciences, 8, pp. 602-625.
32. Lam, J., Takeshita, S., Barker, JE, Kanagawa, O., Ross, FP and Teitelbaum, SL. (2000) TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. Journal of Clinical Investigation, 106, pp. 1481-1488.
33. Li, P., Schwarz, EM, O'Keefe, RJ, Ma, L., Boyce, BF and Xing, L. (2004) RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. Journal of Bone and Mineral Research, 19, pp. 207-213.
34. Lubberts, E., Koenders, MI and van den Berg, WB. (2005) The role of T-cell interleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Research and Therapy, 7, pp. 29-37.
35. Maini, RN, Taylor, PC, Paleolog, E., Charles, P., Ballara, S., Brennan, FM and Feldmann, M. (1999) Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Annals of the Rheumatic Diseases, 58, pp. I56-I60.
36. McInnes, IB and Gracie, JA. (2004) Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. Current Rheumatology Reports, 6, pp. 336-342.
37. McInnes, IB and Schett, G. (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology, 7, pp. 429-442.
38. Molenaar, ET, Voskuyl, AE, Familian, A., van Mierlo, GJ, Dijkmans, BA and Hack, CE. (2001) Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis and Rheumatism, 44, pp. 997-1002.
39. Ochi, S., Shinohara, M., Sato, K., Gober, HJ, Koga, T., Kodama, T., Takai, T., Miyasaka, N. and Takayanagi, H. (2007) Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proceedings of the National Academy of Sciences of the USA, 104, pp. 11394-11399.
40. Oliver, AM, Martin, F., Gartland, GL, Carter, RH and Kearney, JF. (1997) Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. European Journal of Immunology, 27, pp. 2366-2374.
41. Petersen, HH, Nielsen, JP and Heegaard, PM. (2004) Application of acute phase protein measurements in veterinary clinical chemistry. Veterinary Research, 35, pp. 163-187.
42. Pettit, AR, Ji, H., Von SD, Muller, R., Goldring, SR, Choi, Y., Benoist, C. and Gravallese, EM. (2001) TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. American Journal of Pathology, 159, pp. 1689-1699.
43. Punzi, L., Calo, L. and Plebani, M. (2002) Clinical significance of cytokine determination in synovial fluid. Critical Reviews in Clinical Laboratory Sciences, 39, pp. 63-88.
44. Redlich, K., Hayer, S., Maier, A., Dunstan, CR, Tohidast-Akrad, M., Lang, S., Turk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., Kollias, G., Steiner, G., Smolen, JS and Schett, G. (2002) Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis and Rheumatism, 46, pp. 785-792.
45. Richard-Miceli, C. and Dougados, M. (2001) Tumour necrosis factor-alpha blockers in rheumatoid arthritis: Review of the clinical experience. BioDrugs, 15, pp. 251-259.
46. Rioja, I., Bush, KA, Buckton, JB, Dickson, MC and Life, PF. (2004) Joint cytokine quantification in two rodent arthritis models: Kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clinical and Experimental Immunology, 137, pp. 65-73.
47. Roberts, S. and Butler, RC. (2005) Inflammatory mediators as potential therapeutic targets in the spine. Current Drug Targets Inflammation and Allergy, 4, pp. 257-266.
48. Rollins, BJ. (1996) Monocyte chemoattractant protein 1: A potential regulator of monocyte recruitment in inflammatory disease. Molecular Medicine Today, 2, pp. 198-204.
49. Romas, E., Sims, NA, Hards, DK, Lindsay, M., Quinn, JW, Ryan, PF, Dunstan, CR, Martin, TJ and Gillespie, MT. (2002) Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. American Journal of Pathology, 161, pp. 1419-1427.
50. Rosengren, S., Firestein, GS and Boyle, DL. (2003) Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clinical and Diagnostic Laboratory Immunology, 10, pp. 1002-1010.
51. Schett, G., Middleton, S., Bolon, B., Stolina, M., Brown, H., Zhu, L., Pretorius, J., Zack, DJ, Kostenuik, P. and Feige, U. (2005) Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis and Rheumatism, 52, pp. 1604-1611.
52. Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Gortz, B., Schulz, A., Bergmeister, H., Kollias, G., Steiner, G. and Smolen, JS. (2003) Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis and Rheumatism, 48, pp. 2042-2051.
53. Schulze-Koops, H. and Kalden, JR. (2001) The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 15, pp. 677-691.
54. Steiner, G., Tohidast-Akrad, M., Witzmann, G., Vesely, M., Studnicka-Benke, A., Gal, A., Kunaver, M., Zenz, P. and Smolen, JS. (1999) Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford), 38, pp. 202-213.
55. Stolina, M., Adamu, S., Ominsky, M., Dwyer, D., Asuncion, F., Geng, Z., Middleton, S., Brown, H., Pretorius, J., Schett, G., Bolon, B., Feige, U., Zack, D. and Kostenuik, PJ. (2005) RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. Journal of Bone and Mineral Research, 20, pp. 1756-1765.
56. Stolina, M., Bolon, B., Middleton, S., Dwyer, D., Brown, H., Duryea, D., Zhu, L., Rohner, A., Pretorius, J., Kostenuik, P., Feige, U. and Zack, D. (2008) The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. Journal of Clinical Immunology
57. Taylor, PC. (2003) Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Current Pharmaceutical Design, 9, pp. 1095-1106.
58. van den Berg, W. (2001) Cytokines in bone and cartilage destruction and repair. Journal of Clinical Rheumatology, 7, pp. S8-S11.
59. Wei, S., Kitaura, H., Zhou, P., Ross, FP and Teitelbaum, SL. (2005) IL-1 mediates TNF-induced osteoclastogenesis. Journal of Clinical Investigation, 115, pp. 282-290.
60. Wooley, PH, Dutcher, J., Widmer, MB and Gillis, S. (1993) Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. Journal of Immunology, 151, pp. 6602-6607.
61. Wooley, PH, Whalen, JD, Chapman, DL, Berger, AE, Richard, KA, Aspar, DG and Staite, ND. (1993) The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis and Rheumatism, 36, pp. 1305-1314.